A modified portion of the human growth hormone (HGH) molecule is referred to as the HGH fragment 176-191. It is commonly referred to as “tyr-hGH177-191” and “Anti-Obesity Drug (AOD) 9604” among members of the scientific community.
Due to the fact that it is derived from the last section of the HGH molecule, it is commonly known as a medication that helps combat obesity. That is the portion of the hormone that is responsible for the special fat-burning properties that it contains.
Therefore, the purpose of AOD 9604 is to hasten the process of losing weight without causing an increase in IGF-1 or insulin resistance.
In spite of the fact that a great number of websites on the internet may assert that HGH fragment 176-191 is a secure and FDA-approved peptide, the fact of the matter is that this peptide has not been authorised by even a single government health authority anywhere in the world.
In point of fact, this medicine’s development was halted in 2007 due to the fact that it was useless, and the substance has never been made or supplied for the purpose of therapeutic usage. For the time being, the peptide is solely available for usage in research settings.
Is there any truth to the HGH Fragment hype?
In their research, scientists discovered that various components of the HGH molecule have a variety of impacts.
Only the 15 amino acids listed at the end of the hormone’s sequence are the ones that are responsible for mediating the fat-burning capabilities of the hormone, out of a total of 191 amino acids. The fragment was referred to be HGH 177-191 or AOD 9401 when it was first discovered.
That was altered by the researchers by the addition of tyrosine in order to assist in the stabilisation of the molecule. This resulted in the formation of a 16-amino acid fragment known as AOD 9604. In contrast to the vast majority of other peptides, this rendered the HGH fragment 176-191 more stable and oral active.
Research on AOD 9604 has primarily been carried out in animal tests on rodents like mice and rabbits. One of the most important trials involves giving excessive amounts of the peptide in the form of oral dosages to obese Zucker rats. This resulted in a bodyweight reduction of fifty percent in just nineteen days.
However, the fragment does not exhibit any of the other effects of HGH, such as an increase in IGF-1 or insulin resistance, or a proliferation of cells. As a result, the chemical does not have the same benefits as growth hormone in terms of maintaining and building muscle.
Unfortunately, clinical trials with actual humans are very difficult to come by, and because the medication has been taken off the market, the majority of the original reports have been lost.
Researchers who had access to some of the data said that the results of the first randomised clinical trial using AOD 9604 showed that obese participants lost up to 2.6 kilogrammes of weight during the course of the study. Oral capsules containing the peptide were given to the participants on a daily basis to be taken for a total of 12 weeks. It’s interesting to see that lower doses worked just as well.
Therefore, the HGH fragment 176-191 might be able to burn fat rather quickly and cause a modest reduction of weight in the span of three months.
However, the researchers also state that a bigger study with 536 patients did not show any substantial weight loss after 24 weeks of regular usage of AOD 9604, which resulted in the cessation of the treatment.
Additional information regarding the topic: the effects of HGH on weight loss
What side effects does the 176-191 fragment of HGH have?
AOD 9604 promotes weight loss by mechanisms that are analogous to those of HGH. Through the activation of a number of different biological pathways, the growth hormone encourages the release of fatty acids from the adipose cells in your body.
The activity of a group of enzymes known as lipases, which are responsible for preventing fat from reaccumulating in your adipose tissues, can be influenced by growth hormone.
HGH frag does not influence the body’s natural production of HGH, nor does it behave in a manner similar to that of a growth hormone secretagogue. There will be no change in the degree to which you are hungry, nor will it stimulate your appetite.
In experiments on animals, the effects of administering 250 mg/kg/day of AOD9604 or 1 mg/kg/day of HGH for a period of 14 days produced varying outcomes depending on whether the mice were lean or obese.
HGH, but not AOD 9604 or the placebo, led to an increase in lean body mass in mice who were already slender. It would appear that the HGH Fragment 176-191 supplement is not an efficient means of increasing muscle mass.
The effects of AOD9604 and HGH in mice with a reduced body fat content
Both HGH and AOD 9604 led to a reduction in body weight in the obese mice that were tested. The researchers found that those given HGH experienced a reduction in adipose tissue that was 28 percentage points greater than those given AOD 9604.
The effects of AOD9604 and HGH on mice with a reduced body fat
Experiments have shown that the HGH fragment 176-191 is a less effective fat burner than HGH itself, contrary to what the majority of web sites could lead you to believe.
It is likely that the effects that growth hormone has on insulin resistance result in increased fat burning. It does this by inhibiting glucose uptake, which in turn causes cells to take in more fat. The insulin resistance caused by the fragment is not increased, in contrast to HGH.
Anecdotal information suggests that one of the benefits of AOD 9604 is a possible modest improvement in insulin sensitivity as well as a slight rise in total cholesterol levels.
Injecting the peptide into the joint may induce cartilage regeneration and connective tissue repair, according to preliminary findings derived from trials conducted on animals. On the other hand, there are not enough studies on humans.
Under the designation, researchers are conducting tests to determine whether or not is beneficial in the treatment of pain. The preliminary findings, however, do not give a positive impression.
HGH fragment 176-191 side effects
Animal investigations have revealed that HGH fragment 176-191 has an excellent safety profile. The oral administration of the drug over an extended period of time was very well handled by mice, swine, and primates.
In the limited number of clinical tests that have been conducted to this point, the peptide has not been shown to produce any major adverse effects, according to the researchers.
The drug has been given to the patient either through an intravenous infusion or in tablet form to take orally. Headaches, chest tightness, palpitations, and euphoric emotions were some of the adverse responses that may have been caused by the peptide.
Since AOD 9604 does not cause an increase in IGF-1 and does not have the mitogenic activity of HGH, it is possible that it is safe to use in individuals who have cancer. Because there is little mitogenic activity, there is also very little chance that the risk of developing cancer will increase. On the other hand, its safety in such circumstances has not yet been assessed.
In addition, it is unknown whether or not AOD 9604 can produce any other adverse effects, such as hair loss, exhaustion, or any other similar symptoms.
How to use it and put it away Fragment 176-191
HGH fragment 176-191 has never been produced for the purpose of medicinal usage by any of the world’s major pharmaceutical companies. Only for the purposes of study was it ever utilised, and subsequently it was put out of use.
Therefore, the quality of any things that can be purchased via the internet is not regulated in any way. There is absolutely no assurance that these items are risk-free or efficient in any way.
It is strongly recommended that you do not make use of fragment 176-191 or any other peptides that are not approved by the FDA.
The scant information from human research has solely investigated the safety of oral administration and intravenous infusions of the drug.
However, the peptide is frequently administered subcutaneously by athletes and bodybuilders in an effort to accelerate fat burning and make it simpler to achieve their weight loss goals. There has never been any research done on people involving the subcutaneous administration of HGH fragment 176-191.
In addition, it is occasionally utilised in stacks with other peptides, which are combinations of peptides that are intended to boost the efficiency of the first peptide. However, there is no formal information regarding the efficacy or safety of such combinations.
At this time, there are no formal recommendations regarding the correct manner in which to store products of this kind.
Instructions for the mixture and the amount to take
According to the official safety data that we have access to, AOD 9604 has been safely utilised in the course of study as an intravenous infusion in doses ranging from 25 micrograms to 400 micrograms per kilogramme of bodyweight.
The medicine has been used orally, either as tablets or capsules, in doses ranging from 0.25 mg (250 g) to 54 mg on a daily basis.
In one of the trials that indicated some advantages for weight loss, the lowest dosage (1 mg/day) was considerably more beneficial than larger dosages (5-30 mg/day) or a placebo. This was the case regardless of whether the study used phentermine or a placebo.
HGH fragment 176-191 is typically sold as a prohibited performance-enhancing drug and is distributed in the form of vials containing 5 mg of lyophilized powder. This powder needs to be reconstituted with bacteriostatic water before it can be injected subcutaneously.
However, there is a significant amount of disagreement among the many recommendations because the majority of them are founded on personal experience and hearsay. The majority of the publications I looked at suggested daily doses of 250-350 micrograms administered anywhere from once to three times.